> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Sage/Biogen Nix Expanded Use for Zurzuvae
- URL: https://www.fdaweb.com/sage-biogen-nix-expanded-use-for-zurzuvae/
- Published: 2024-10-30T12:00:00.000Z
- Updated: 2026-09-14T14:45:45.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5158084

Sage Therapeutics and Biogen say they will not seek an expanded use (major depressive disorder (MDD)) for postpartum depression (PPD) drug Zurzuvae (zuranolone). In 2023, FDA issued a complete response letter on an NDA seeking approval for zuranolone in the treatment of adults with MDD. “Sage and Biogen will not pursue further development of zuranolone as a treatment for MDD in the U.S. based on the significant new investment and time we expect would be needed to conduct additional studies,” a news release says, adding that they plan to prioritize resources on supporting the PPD patient community.